Wedbush Downgrades Zentalis Pharmaceuticals (ZNTL) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts ZNTL Hot Sheet
Price: $1.96 --0%
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 16 | New: 15
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 16 | New: 15
Join SI Premium – FREE
Wedbush analyst Robert Driscoll downgraded Zentalis Pharmaceuticals (NASDAQ: ZNTL) from Outperform to Neutral with a price target of $12.00 (from $38.00).
For an analyst ratings summary and ratings history on Zentalis Pharmaceuticals click here. For more ratings news on Zentalis Pharmaceuticals click here.
Shares of Zentalis Pharmaceuticals closed at $10.20 yesterday.
You May Also Be Interested In
- Texas Capital Securities Downgrades Full House Resorts (FLL) to Hold
- Chubu Electric Power Company (9502:JP) (CHUEF) PT Raised to JPY3,130 at Nomura/Instinet
- ICON plc (ICLR) PT Raised to $228 at Mizuho
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
